Rho激酶特异性抑制剂H1152对内皮祖细胞数量及迁移的增强作用
Enhancement of endothelial progenitor cell numbers and migration by H1152, a Rho kinase specific inhibitor.
作者信息
O Eunju, Lee Seung Woo, Lee Hyun-Sun, Lim Hee-Suk, Ahn Hyun-Young, Shin Jong-Chul, Kim Yonggoo, Joe Young Ae
机构信息
Cancer Research Institute and Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Seoul, Korea.
出版信息
Biosci Biotechnol Biochem. 2012;76(1):172-5. doi: 10.1271/bbb.110468. Epub 2012 Jan 7.
Endothelial progenitor cells (EPCs) are applied in the treatment of ischemic diseases. In ex vivo culture of human cord-blood derived EPCs, H1152, (S)-(+)-2-methyl-1-[(4-methyl-5-iso-quinolinyl) sulfonyl]-homopiperazine, markedly increased the number of EPCs. It also induced EPC migration, stimulated the phosphorylation of AKT, and reduced the expression of p27 in the EPCs. Thus H1152 can be used effectively in ex vivo expansion of EPCs.
内皮祖细胞（EPCs）被应用于缺血性疾病的治疗。在人脐带血来源的EPCs的体外培养中，H1152，即（S）-（+）-2-甲基-1-[(4-甲基-5-异喹啉基)磺酰基]-高哌嗪，显著增加了EPCs的数量。它还诱导EPCs迁移，刺激AKT的磷酸化，并降低EPCs中p27的表达。因此，H1152可有效地用于EPCs的体外扩增。
Zotero 插件